Top

Published in:

01-01-2022 | Myelodysplastic Syndrome | News item

Risk of differentiation syndrome with decitabine, warns the NPRA in Malaysia

Published in: Reactions Weekly | Issue 1/2022

Excerpt

The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has issued a warning to raise awareness of a potentially life-threatening adverse effect called differentiation syndrome¹ in patients receiving decitabine. …

formerly retinoic acid syndrome

Ministry of Health Malaysia. Decitabine: Risk of Differentiation Syndrome Internet Document : 21 Dec 2021. Available from: URL: https://npra.gov.my/index.php/en/component/content/article/426-english/safety-alerts-main/safety-alerts-2021/1527272-decitabine-risk-of-differentiation-syndrome.html?Itemid=1391

Title: Risk of differentiation syndrome with decitabine, warns the NPRA in Malaysia
Publication date: 01-01-2022
Publisher: Springer International Publishing
Keywords: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Pleural Effusion
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-07668-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk of differentiation syndrome with decitabine, warns the NPRA in Malaysia

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Osimertinib

Amiodarone/ivabradine/propranolol

Atezolizumab

Ciclosporin/methylprednisolone

Methylprednisolone

Cisplatin